Quantitative proteomics of kinase inhibitor targets and mechanisms

ACS Chemical Biology

Volumn 10, Issue 1, 2015, Pages 201-212

  Daub, Henrik ^a  

^a Evotec München GmbH Dept of Bioinformatics   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL EXTRACT; PHOSPHOTRANSFERASE INHIBITOR; PROTEOME; IMMOBILIZED ENZYME; MOLECULAR LIBRARY; PROTEIN BINDING; PROTEIN KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG SELECTIVITY; MASS SPECTROMETRY; MEDICAL RESEARCH; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PHOSPHORYLATION; PROCEDURES;

ANIMALS; DRUG DISCOVERY; ENZYMES, IMMOBILIZED; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTEOMICS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84921346191     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5008794     Document Type: Article

References (119)

1. Manning, G., Whyte, D. B., Martinez, R., Hunter, T., and Sudarsanam, S. (2002) The protein kinase complement of the human genome Science 298, 1912-1934
2. Blume-Jensen, P. and Hunter, T. (2001) Oncogenic kinase signalling Nature 411, 355-365
3. Cohen, P. (2002) Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug. Discovery 1, 309-315
4. Zhang, J., Yang, P. L., and Gray, N. S. (2009) Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9, 28-39
5. Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H., and Peterson, J. R. (2011) Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity Nat. Biotechnol. 29, 1039-1045
6. Cong, F., Cheung, A. K., and Huang, S. M. (2012) Chemical genetics-based target identification in drug discovery Annu. Rev. Pharmacol. Toxicol. 52, 57-78
7. Roux, P. P. and Thibault, P. (2013) The coming of age of phosphoproteomics - from large data sets to inference of protein functions Mol. Cell. Proteomics 12, 3453-3464
8. Rix, U. and Superti-Furga, G. (2009) Target profiling of small molecules by chemical proteomics Nat. Chem. Biol. 5, 616-624
9. Bantscheff, M., Scholten, A., and Heck, A. J. (2009) Revealing promiscuous drug-target interactions by chemical proteomics Drug Discovery Today 14, 1021-1029
10. Choudhary, C. and Mann, M. (2010) Decoding signalling networks by mass spectrometry-based proteomics Nat. Rev. Mol. Cell Biol. 11, 427-439
11. Junger, M. A. and Aebersold, R. (2014) Mass spectrometry-driven phosphoproteomics: patterning the systems biology mosaic Wiley Interdiscip. Rev. Dev. Biol. 3, 83-112
12. Lee, J. and Bogyo, M. (2013) Target deconvolution techniques in modern phenotypic profiling Curr. Opin. Chem. Biol. 17, 118-126
13. Gao, Y., Davies, S. P., Augustin, M., Woodward, A., Patel, U. A., Kovelman, R., and Harvey, K. J. (2013) A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery Biochem. J. 451, 313-328
14. Davis, M. I., Hunt, J. P., Herrgard, S., Ciceri, P., Wodicka, L. M., Pallares, G., Hocker, M., Treiber, D. K., and Zarrinkar, P. P. (2011) Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 29, 1046-1051
15. Kitagawa, D., Yokota, K., Gouda, M., Narumi, Y., Ohmoto, H., Nishiwaki, E., Akita, K., and Kirii, Y. (2013) Activity-based kinase profiling of approved tyrosine kinase inhibitors Genes Cells 18, 110-122
16. Swanson, K. D., Taylor, L. K., Haung, L., Burlingame, A. L., and Landreth, G. E. (1999) Transcription factor phosphorylation by pp90(rsk2). Identification of Fos kinase and NGFI-B kinase I as pp90(rsk2) J. Biol. Chem. 274, 3385-3395
17. Knockaert, M., Gray, N., Damiens, E., Chang, Y. T., Grellier, P., Grant, K., Fergusson, D., Mottram, J., Soete, M., Dubremetz, J. F., Le Roch, K., Doerig, C., Schultz, P., and Meijer, L. (2000) Intracellular targets of cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors Chem. Biol. 7, 411-422
18. Bach, S., Knockaert, M., Reinhardt, J., Lozach, O., Schmitt, S., Baratte, B., Koken, M., Coburn, S. P., Tang, L., Jiang, T., Liang, D. C., Galons, H., Dierick, J. F., Pinna, L. A., Meggio, F., Totzke, F., Schachtele, C., Lerman, A. S., Carnero, A., Wan, Y., Gray, N., and Meijer, L. (2005) Roscovitine targets, protein kinases and pyridoxal kinase J. Biol. Chem. 280, 31208-31219
19. Ding, S., Wu, T. Y., Brinker, A., Peters, E. C., Hur, W., Gray, N. S., and Schultz, P. G. (2003) Synthetic small molecules that control stem cell fate Proc. Natl. Acad. Sci. U.S.A. 100, 7632-7637
20. Wan, Y., Hur, W., Cho, C. Y., Liu, Y., Adrian, F. J., Lozach, O., Bach, S., Mayer, T., Fabbro, D., Meijer, L., and Gray, N. S. (2004) Synthesis and target identification of hymenialdisine analogs Chem. Biol. 11, 247-259
21. Godl, K., Wissing, J., Kurtenbach, A., Habenberger, P., Blencke, S., Gutbrod, H., Salassidis, K., Stein-Gerlach, M., Missio, A., Cotten, M., and Daub, H. (2003) An efficient proteomics method to identify the cellular targets of protein kinase inhibitors Proc. Natl. Acad. Sci. U.S.A. 100, 15434-15439
22. Wissing, J., Godl, K., Brehmer, D., Blencke, S., Weber, M., Habenberger, P., Stein-Gerlach, M., Missio, A., Cotten, M., Muller, S., and Daub, H. (2004) Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors Mol. Cell. Proteomics 3, 1181-1193
23. Godl, K., Gruss, O. J., Eickhoff, J., Wissing, J., Blencke, S., Weber, M., Degen, H., Brehmer, D., Orfi, L., Horvath, Z., Keri, G., Muller, S., Cotten, M., Ullrich, A., and Daub, H. (2005) Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signaling Cancer Res. 65, 6919-6926
24. Brehmer, D., Greff, Z., Godl, K., Blencke, S., Kurtenbach, A., Weber, M., Muller, S., Klebl, B., Cotten, M., Keri, G., Wissing, J., and Daub, H. (2005) Cellular targets of gefitinib Cancer Res. 65, 379-382
25. Tigno-Aranjuez, J. T., Benderitter, P., Rombouts, F., Deroose, F., Bai, X., Mattioli, B., Cominelli, F., Pizarro, T. T., Hoflack, J., and Abbott, D. W. (2014) In Vivo Inhibition of RIPK2 Kinase Alleviates Inflammatory Disease J. Biol. Chem. 289, 29651-29664
26. Tigno-Aranjuez, J. T., Asara, J. M., and Abbott, D. W. (2010) Inhibition of RIP2s tyrosine kinase activity limits NOD2-driven cytokine responses Genes Dev. 24, 2666-2677
27. Remsing Rix, L. L., Rix, U., Colinge, J., Hantschel, O., Bennett, K. L., Stranzl, T., Muller, A., Baumgartner, C., Valent, P., Augustin, M., Till, J. H., and Superti-Furga, G. (2009) Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells Leukemia 23, 477-485
28. Rix, U., Hantschel, O., Durnberger, G., Remsing Rix, L. L., Planyavsky, M., Fernbach, N. V., Kaupe, I., Bennett, K. L., Valent, P., Colinge, J., Kocher, T., and Superti-Furga, G. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets Blood 110, 4055-4063
29. Remsing Rix, L. L., Kuenzi, B. M., Luo, Y., Remily-Wood, E., Kinose, F., Wright, G., Li, J., Koomen, J. M., Haura, E. B., Lawrence, H. R., and Rix, U. (2013) GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells ACS Chem. Biol. 9, 353-358
30. Brehmer, D., Godl, K., Zech, B., Wissing, J., and Daub, H. (2004) Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors Mol. Cell. Proteomics 3, 490-500
31. Missner, E., Bahr, I., Badock, V., Lucking, U., Siemeister, G., and Donner, P. (2009) Off-target decoding of a multitarget kinase inhibitor by chemical proteomics Chembiochem 10, 1163-1174
32. Bantscheff, M., Lemeer, S., Savitski, M. M., and Kuster, B. (2012) Quantitative mass spectrometry in proteomics: critical review update from 2007 to the present Anal. Bioanal. Chem. 404, 939-965
33. Cox, J., Neuhauser, N., Michalski, A., Scheltema, R. A., Olsen, J. V., and Mann, M. (2011) Andromeda: a peptide search engine integrated into the MaxQuant environment J. Proteome Res. 10, 1794-1805
34. Oda, Y., Owa, T., Sato, T., Boucher, B., Daniels, S., Yamanaka, H., Shinohara, Y., Yokoi, A., Kuromitsu, J., and Nagasu, T. (2003) Quantitative chemical proteomics for identifying candidate drug targets Anal. Chem. 75, 2159-2165
35. Zhang, Y. X., Knyazev, P. G., Cheburkin, Y. V., Sharma, K., Knyazev, Y. P., Orfi, L., Szabadkai, I., Daub, H., Keri, G., and Ullrich, A. (2008) AXL is a potential target for therapeutic intervention in breast cancer progression Cancer Res. 68, 1905-1915
36. Ong, S. E., Schenone, M., Margolin, A. A., Li, X., Do, K., Doud, M. K., Mani, D. R., Kuai, L., Wang, X., Wood, J. L., Tolliday, N. J., Koehler, A. N., Marcaurelle, L. A., Golub, T. R., Gould, R. J., Schreiber, S. L., and Carr, S. A. (2009) Identifying the proteins to which small-molecule probes and drugs bind in cells Proc. Natl. Acad. Sci. U.S.A 106, 4617-4622
37. Zhang, L., Holmes, I. P., Hochgrafe, F., Walker, S. R., Ali, N. A., Humphrey, E. S., Wu, J., de Silva, M., Kersten, W. J., Connor, T., Falk, H., Allan, L., Street, I. P., Bentley, J. D., Pilling, P. A., Monahan, B. J., Peat, T. S., and Daly, R. J. (2013) Characterization of the novel broad-spectrum kinase inhibitor CTx-0294885 as an affinity reagent for mass spectrometry-based kinome profiling J. Proteome Res. 12, 3104-3116
38. Sharma, K., Weber, C., Bairlein, M., Greff, Z., Keri, G., Cox, J., Olsen, J. V., and Daub, H. (2009) Proteomics strategy for quantitative protein interaction profiling in cell extracts Nat. Methods 6, 741-744
39. Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., Mathieson, T., Perrin, J., Raida, M., Rau, C., Reader, V., Sweetman, G., Bauer, A., Bouwmeester, T., Hopf, C., Kruse, U., Neubauer, G., Ramsden, N., Rick, J., Kuster, B., and Drewes, G. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25, 1035-1044
40. Oppermann, F. S., Gnad, F., Olsen, J. V., Hornberger, R., Greff, Z., Keri, G., Mann, M., and Daub, H. (2009) Large-scale proteomics analysis of the human kinome Mol. Cell. Proteomics 8, 1751-1764
41. Kuai, L., Ong, S. E., Madison, J. M., Wang, X., Duvall, J. R., Lewis, T. A., Luce, C. J., Conner, S. D., Pearlman, D. A., Wood, J. L., Schreiber, S. L., Carr, S. A., Scolnick, E. M., and Haggarty, S. J. (2011) AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics Chem. Biol. 18, 891-906
42. Aye, T. T., Mohammed, S., Toorn, H. W., Veen, T. A., Heyden, M. A., Scholten, A., and Heck, A. J. (2008) Selectivity in enrichment of PKA RI and RII isoforms, their interactors using modified cAMP affinity resins Mol. Cell. Proteomics 8, 1016-1028
43. Golkowski, M., Brigham, J. L., Perera, G. K., Romano, G. E., Maly, D. J., and Ong, S. E. (2014) Rapid profiling of protein kinase inhibitors by quantitative proteomics Medchemcomm 5, 363-369
44. Szklarczyk, D., Franceschini, A., Kuhn, M., Simonovic, M., Roth, A., Minguez, P., Doerks, T., Stark, M., Muller, J., Bork, P., Jensen, L. J., and von Mering, C. (2011) The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored Nucleic Acids Res. 39, D561-568
45. Conradt, L., Godl, K., Schaab, C., Tebbe, A., Eser, S., Diersch, S., Michalski, C. W., Kleeff, J., Schnieke, A., Schmid, R. M., Saur, D., and Schneider, G. (2011) Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma Neoplasia 13, 1026-1034
46. Weber, C., Schreiber, T. B., and Daub, H. (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells J. Proteomics 75, 1343-1356
47. Augustin, A., Lamerz, J., Meistermann, H., Golling, S., Scheiblich, S., Hermann, J. C., Duchateau-Nguyen, G., Tzouros, M., Avila, D. W., Langen, H., Essioux, L., and Klughammer, B. (2014) Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines Mol. Cancer Ther. 12, 520-529
48. Colzani, M., Noberini, R., Romanenghi, M., Colella, G., Pasi, M., Fancelli, D., Varasi, M., Minucci, S., and Bonaldi, T. (2014) Quantitative chemical proteomics identifies novel targets of the anti-cancer multi-kinase inhibitor E-3810 Mol. Cell. Proteomics 13, 1495-1509
49. Wissing, J., Jansch, L., Nimtz, M., Dieterich, G., Hornberger, R., Keri, G., Wehland, J., and Daub, H. (2007) Proteomics analysis of protein kinases by target class-selective prefractionation and tandem mass spectrometry Mol. Cell. Proteomics 6, 537-547
50. Kruse, U., Pallasch, C. P., Bantscheff, M., Eberhard, D., Frenzel, L., Ghidelli, S., Maier, S. K., Werner, T., Wendtner, C. M., and Drewes, G. (2011) Chemoproteomics-based kinome profiling and target deconvolution of clinical multi-kinase inhibitors in primary chronic lymphocytic leukemia cells Leukemia 25, 89-100
51. Urbaniak, M. D., Mathieson, T., Bantscheff, M., Eberhard, D., Grimaldi, R., Miranda-Saavedra, D., Wyatt, P., Ferguson, M. A., Frearson, J., and Drewes, G. (2012) Chemical proteomic analysis reveals the drugability of the kinome of Trypanosoma brucei ACS Chem. Biol. 7, 1858-1865
52. Delehouze, C., Godl, K., Loaec, N., Bruyere, C., Desban, N., Oumata, N., Galons, H., Roumeliotis, T. I., Giannopoulou, E. G., Grenet, J., Twitchell, D., Lahti, J., Mouchet, N., Galibert, M. D., Garbis, S. D., and Meijer, L. (2014) CDK/CK1 inhibitors roscovitine and CR8 downregulate amplified MYCN in neuroblastoma cells Oncogene 33, 5675-5687
53. Pachl, F., Plattner, P., Ruprecht, B., Medard, G., Sewald, N., and Küster, B. (2013) Characterization of a chemical affinity probe targeting Akt kinases J. Proteome Res. 12, 3792-3800
54. Ku, X., Heinzlmeir, S., Liu, X., Medard, G., and Kuster, B. (2014) A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors J. Proteomics 96, 44-55
55. Ku, X., Heinzlmeir, S., Helm, D., Medard, G., and Kuster, B. (2014) New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics J. Proteome Res. 13, 2445-2452
56. Becher, I., Savitski, M. M., Savitski, M. F., Hopf, C., Bantscheff, M., and Drewes, G. (2013) Affinity profiling of the cellular kinome for the nucleotide cofactors ATP and ADP, and GTP ACS Chem. Biol. 8, 599-607
57. Knight, Z. A. and Shokat, K. M. (2005) Features of selective kinase inhibitors Chem. Biol. 12, 621-637
58. Daub, H., Olsen, J. V., Bairlein, M., Gnad, F., Oppermann, F. S., Korner, R., Greff, Z., Keri, G., Stemmann, O., and Mann, M. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle Mol. Cell 31, 438-448
59. Dulla, K., Daub, H., Hornberger, R., Nigg, E. A., and Korner, R. (2010) Quantitative site-specific phosphorylation dynamics of human protein kinases during mitotic progression Mol. Cell. Proteomics 9, 1167-1181
60. Sharma, K., Kumar, C., Keri, G., Breitkopf, S. B., Oppermann, F. S., and Daub, H. (2010) Quantitative analysis of kinase-proximal signaling in lipopolysaccharide-induced innate immune response J. Proteome Res. 9, 2539-2549
61. Breitkopf, S. B., Oppermann, F. S., Keri, G., Grammel, M., and Daub, H. (2010) Proteomics Analysis of Cellular Imatinib Targets and their Candidate Downstream Effectors J. Proteome Res. 9, 6033-6043
62. Wu, Z., Doondeea, J. B., Gholami, A. M., Janning, M. C., Lemeer, S., Kramer, K., Eccles, S. A., Gollin, S. M., Grenman, R., Walch, A., Feller, S. M., and Kuster, B. (2011) Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer Mol. Cell. Proteomics 10, M111 011635
63. Moghaddas Gholami, A., Hahne, H., Wu, Z., Auer, F. J., Meng, C., Wilhelm, M., and Kuster, B. (2013) Global proteome analysis of the NCI-60 cell line panel Cell Rep. 4, 609-620
64. Sos, M. L., Levin, R. S., Gordan, J. D., Oses-Prieto, J. A., Webber, J. T., Salt, M., Hann, B., Burlingame, A. L., McCormick, F., Bandyopadhyay, S., and Shokat, K. M. (2014) Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors Cell Rep. 8, 1037-1048
65. Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., Usary, J., Kuan, P. F., Smalley, D. M., Major, B., He, X., Hoadley, K. A., Zhou, B., Sharpless, N. E., Perou, C. M., Kim, W. Y., Gomez, S. M., Chen, X., Jin, J., Frye, S. V., Earp, H. S., Graves, L. M., and Johnson, G. L. (2012) Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer Cell 149, 307-321
66. Patricelli, M. P., Nomanbhoy, T. K., Wu, J., Brown, H., Zhou, D., Zhang, J., Jagannathan, S., Aban, A., Okerberg, E., Herring, C., Nordin, B., Weissig, H., Yang, Q., Lee, J. D., Gray, N. S., and Kozarich, J. W. (2011) In situ kinase profiling reveals functionally relevant properties of native kinases Chem. Biol. 18, 699-710
67. Xiao, Y., Guo, L., and Wang, Y. (2014) A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues Mol. Cell. Proteomics 13, 1065-1075
68. Lemeer, S., Zorgiebel, C., Ruprecht, B., Kohl, K., and Kuster, B. (2013) Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity J. Proteome Res. 12, 1723-1731
69. Fischer, J. J., Dalhoff, C., Schrey, A. K., Graebner, O. Y., Michaelis, S., Andrich, K., Glinski, M., Kroll, F., Sefkow, M., Dreger, M., and Koester, H. (2011) Dasatinib and imatinib and staurosporine capture compounds-Complementary tools for the profiling of kinases by Capture Compound Mass Spectrometry (CCMS) J. Proteomics 75, 160-168
70. Ranjitkar, P., Perera, B. G., Swaney, D. L., Hari, S. B., Larson, E. T., Krishnamurty, R., Merritt, E. A., Villen, J., and Maly, D. J. (2012) Affinity-based probes based on type II kinase inhibitors J. Am. Chem. Soc. 134, 19017-19025
71. Shi, H., Cheng, X., Sze, S. K., and Yao, S. Q. (2011) Proteome profiling reveals potential cellular targets of staurosporine using a clickable cell-permeable probe Chem. Commun. (Camb) 47, 11306-11308
72. Shi, H., Zhang, C. J., Chen, G. Y., and Yao, S. Q. (2012) Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes J. Am. Chem. Soc. 134, 3001-3014
73. Lanning, B. R., Whitby, L. R., Dix, M. M., Douhan, J., Gilbert, A. M., Hett, E. C., Johnson, T. O., Joslyn, C., Kath, J. C., Niessen, S., Roberts, L. R., Schnute, M. E., Wang, C., Hulce, J. J., Wei, B., Whiteley, L. O., Hayward, M. M., and Cravatt, B. F. (2014) A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors Nat. Chem. Biol. 10, 760-767
74. Savitski, M. M., Reinhard, F. B., Franken, H., Werner, T., Savitski, M. F., Eberhard, D., Martinez Molina, D., Jafari, R., Dovega, R. B., Klaeger, S., Kuster, B., Nordlund, P., Bantscheff, M., and Drewes, G. (2014) Proteomics. Tracking cancer drugs in living cells by thermal profiling of the proteome Science 346, 1255784
75. Martinez Molina, D., Jafari, R., Ignatushchenko, M., Seki, T., Larsson, E. A., Dan, C., Sreekumar, L., Cao, Y., and Nordlund, P. (2013) Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay Science 341, 84-87
76. Moritz, A., Li, Y., Guo, A., Villen, J., Wang, Y., MacNeill, J., Kornhauser, J., Sprott, K., Zhou, J., Possemato, A., Ren, J. M., Hornbeck, P., Cantley, L. C., Gygi, S. P., Rush, J., and Comb, M. J. (2010) Akt-RSK-S6 kinase signaling networks activated by oncogenic receptor tyrosine kinases Sci. Signal 3, ra64
77. Oppermann, F. S., Klammer, M., Bobe, C., Cox, J., Schaab, C., Tebbe, A., and Daub, H. (2013) Comparison of SILAC and mTRAQ quantification for phosphoproteomics on a quadrupole orbitrap mass spectrometer J. Proteome Res. 12, 4089-4100
78. Lundby, A., Andersen, M. N., Steffensen, A. B., Horn, H., Kelstrup, C. D., Francavilla, C., Jensen, L. J., Schmitt, N., Thomsen, M. B., and Olsen, J. V. (2013) In vivo phosphoproteomics analysis reveals the cardiac targets of beta-adrenergic receptor signaling Sci. Signal 6, rs11
79. Sharma, K., DSouza, R. C., Tyanova, S., Schaab, C., Wisniewski, J. R., Cox, J., and Mann, M. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of tyr and ser/thr-based signaling Cell Rep. 8, 1583-1594
80. Yu, Y., Yoon, S. O., Poulogiannis, G., Yang, Q., Ma, X. M., Villen, J., Kubica, N., Hoffman, G. R., Cantley, L. C., Gygi, S. P., and Blenis, J. (2011) Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling Science 332, 1322-1326
81. Humphrey, S. J., Yang, G., Yang, P., Fazakerley, D. J., Stockli, J., Yang, J. Y., and James, D. E. (2013) Dynamic adipocyte phosphoproteome reveals that Akt directly regulates mTORC2 Cell Metab. 17, 1009-1020
82. Pierobon, M., Wulfkuhle, J., Liotta, L., and Petricoin, E. (2014) Application of molecular technologies for phosphoproteomic analysis of clinical samples, Oncogene [Online early access]. DOI: 10.1038/onc.2014.16. Published Online: Mar 10, 2014.
83. Klammer, M., Dybowski, J. N., Hoffmann, D., and Schaab, C. (2014) Identification of significant features by the Global Mean Rank test PLoS One 9, e104504
84. Li, J. 2010, A chemical and phosphoproteomic characterization of dasatinib action in lung cancer Nat. Chem. Biol. 6, 291-299
85. Yoshida, T., Zhang, G., Smith, M. A., Lopez, A. S., Bai, Y., Li, J., Fang, B., Koomen, J., Rawal, B., Fisher, K. J., Chen, A. Y., Kitano, M., Morita, Y., Yamaguchi, H., Shibata, K., Okabe, T., Okamoto, I., Nakagawa, K., and Haura, E. B. (2014) Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer Clin. Cancer Res. 20, 4059-4074
86. Guo, A., Villen, J., Kornhauser, J., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A., Nardone, J., Innocenti, G., Wetzel, R., Wang, Y., MacNeill, J., Mitchell, J., Gygi, S. P., Rush, J., Polakiewicz, R. D., and Comb, M. J. (2008) Signaling networks assembled by oncogenic EGFR and c-Met Proc. Natl. Acad. Sci. U.S.A. 105, 692-697
87. Tzouros, M., Golling, S., Avila, D., Lamerz, J., Berrera, M., Ebeling, M., Langen, H., and Augustin, A. (2013) Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics Mol. Cell. Proteomics 12, 3339-3349
88. Xue, L., Geahlen, R. L., and Tao, W. A. (2013) Identification of direct tyrosine kinase substrates based on protein kinase assay-linked phosphoproteomics Mol. Cell. Proteomics 12, 2969-2980
89. Imami, K., Sugiyama, N., Imamura, H., Wakabayashi, M., Tomita, M., Taniguchi, M., Ueno, T., Toi, M., and Ishihama, Y. (2012) Temporal profiling of lapatinib-suppressed phosphorylation signals in EGFR/HER2 pathways Mol. Cell. Proteomics 11, 1741-1757
90. Pan, C., Olsen, J. V., Daub, H., and Mann, M. (2009) Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics Mol. Cell. Proteomics 8, 2796-2808
91. Courcelles, M., Fremin, C., Voisin, L., Lemieux, S., Meloche, S., and Thibault, P. (2013) Phosphoproteome dynamics reveal novel ERK1/2 MAP kinase substrates with broad spectrum of functions Mol. Syst. Biol. 9, 669
92. Xue, L., Wang, P., Cao, P., Zhu, J. K., and Tao, W. A. (2014) Identification of Extracellular Signal-regulated Kinase 1 (ERK1) Direct Substrates using Stable Isotope Labeled Kinase Assay-Linked Phosphoproteomics Mol. Cell. Proteomics 13, 3199-3210
93. Carlson, S. M., Chouinard, C. R., Labadorf, A., Lam, C. J., Schmelzle, K., Fraenkel, E., and White, F. M. (2011) Large-scale discovery of ERK2 substrates identifies ERK-mediated transcriptional regulation by ETV3 Sci. Signal 4, rs11
94. Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., Marto, J. A., and Sabatini, D. M. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling Science 332, 1317-1322
95. Chen, R. Q., Yang, Q. K., Lu, B. W., Yi, W., Cantin, G., Chen, Y. L., Fearns, C., Yates, J. R., 3rd, and Lee, J. D. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells Cancer Res. 69, 2663-2668
96. Olsen, J. V., Vermeulen, M., Santamaria, A., Kumar, C., Miller, M. L., Jensen, L. J., Gnad, F., Cox, J., Jensen, T. S., Nigg, E. A., Brunak, S., and Mann, M. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis Sci. Signal 3, ra3
97. Kettenbach, A. N., Schweppe, D. K., Faherty, B. K., Pechenick, D., Pletnev, A. A., and Gerber, S. A. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells Sci. Signal 4, rs5
98. Santamaria, A., Wang, B., Elowe, S., Malik, R., Zhang, F., Bauer, M., Schmidt, A., Sillje, H. H., Korner, R., and Nigg, E. A. (2011) The Plk1-dependent phosphoproteome of the early mitotic spindle Mol. Cell. Proteomics 10, M110 004457
99. Grosstessner-Hain, K., Hegemann, B., Novatchkova, M., Rameseder, J., Joughin, B. A., Hudecz, O., Roitinger, E., Pichler, P., Kraut, N., Yaffe, M. B., Peters, J. M., and Mechtler, K. (2011) Quantitative phospho-proteomics to investigate the polo-like kinase 1-dependent phospho-proteome Mol. Cell. Proteomics 10, M111 008540
100. Raab, M., Pachl, F., Kramer, A., Kurunci-Csacsko, E., Dotsch, C., Knecht, R., Becker, S., Kuster, B., and Strebhardt, K. (2014) Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells Cell Res. 24, 1141-1145
101. Holt, L. J., Tuch, B. B., Villen, J., Johnson, A. D., Gygi, S. P., and Morgan, D. O. (2009) Global analysis of Cdk1 substrate phosphorylation sites provides insights into evolution Science 325, 1682-1686
102. Blasius, M., Forment, J. V., Thakkar, N., Wagner, S. A., Choudhary, C., and Jackson, S. P. (2011) A phospho-proteomic screen identifies substrates of the checkpoint kinase Chk1 Genome Biol. 12, R78
103. Koch, A. and Hauf, S. (2010) Strategies for the identification of kinase substrates using analog-sensitive kinases Eur. J. Cell. Biol. 89, 184-193
104. Bishop, A. C., Ubersax, J. A., Petsch, D. T., Matheos, D. P., Gray, N. S., Blethrow, J., Shimizu, E., Tsien, J. Z., Schultz, P. G., Rose, M. D., Wood, J. L., Morgan, D. O., and Shokat, K. M. (2000) A chemical switch for inhibitor-sensitive alleles of any protein kinase Nature 407, 395-401
105. Oppermann, F. S., Grundner-Culemann, K., Kumar, C., Gruss, O. J., Jallepalli, P. V., and Daub, H. (2012) Combination of chemical genetics and phosphoproteomics for kinase signaling analysis enables confident identification of cellular downstream targets Mol. Cell. Proteomics 11, O111 012351
106. Harrison, M. M., Jenkins, B. V., OConnor-Giles, K. M., and Wildonger, J. (2014) A CRISPR view of development Genes Dev. 28, 1859-1872
107. Winter, G. E., Rix, U., Carlson, S. M., Gleixner, K. V., Grebien, F., Gridling, M., Muller, A. C., Breitwieser, F. P., Bilban, M., Colinge, J., Valent, P., Bennett, K. L., White, F. M., and Superti-Furga, G. (2012) Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML Nat. Chem. Biol. 8, 905-912
108. Giansanti, P., Preisinger, C., Huber, K. V., Gridling, M., Superti-Furga, G., Bennett, K. L., and Heck, A. J. (2014) Evaluating the promiscuous nature of tyrosine kinase inhibitors assessed in A431 epidermoid carcinoma cells by both chemical- and phosphoproteomics ACS Chem. Biol. 9, 1490-1498
109. Kristensen, V. N., Lingjaerde, O. C., Russnes, H. G., Vollan, H. K., Frigessi, A., and Borresen-Dale, A. L. (2014) Principles and methods of integrative genomic analyses in cancer Nat. Rev. Cancer 14, 299-313
110. Alcolea, M. P., Casado, P., Rodriguez-Prados, J. C., Vanhaesebroeck, B., and Cutillas, P. R. (2014) Phosphoproteomic analysis of leukemia cells under basal and drug-treated conditions identifies markers of kinase pathway activation and mechanisms of resistance Mol. Cell. Proteomics 11, 453-466
111. Casado, P., Alcolea, M. P., Iorio, F., Rodriguez-Prados, J. C., Vanhaesebroeck, B., Saez-Rodriguez, J., Joel, S., and Cutillas, P. R. (2013) Phosphoproteomics data classify hematological cancer cell lines according to tumor type and sensitivity to kinase inhibitors Genome Biol. 14, R37
112. Klammer, M., Kaminski, M., Zedler, A., Oppermann, F., Blencke, S., Marx, S., Muller, S., Tebbe, A., Godl, K., and Schaab, C. (2012) Phosphosignature Predicts Dasatinib Response in Non-small Cell Lung Cancer Mol. Cell. Proteomics 11, 651-668
113. Schaab, C., Oppermann, F. S., Klammer, M., Pfeifer, H., Tebbe, A., Oellerich, T., Krauter, J., Levis, M., Perl, A. E., Daub, H., Steffen, B., Godl, K., and Serve, H. (2014) Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib Leukemia 28, 716-719
114. Mertins, P., Yang, F., Liu, T., Mani, D. R., Petyuk, V. A., Gillette, M. A., Clauser, K. R., Qiao, J. W., Gritsenko, M. A., Moore, R. J., Levine, D. A., Townsend, R., Erdmann-Gilmore, P., Snider, J. E., Davies, S. R., Ruggles, K. V., Fenyo, D., Kitchens, R. T., Li, S., Olvera, N., Dao, F., Rodriguez, H., Chan, D. W., Liebler, D., White, F., Rodland, K. D., Mills, G. B., Smith, R. D., Paulovich, A. G., Ellis, M., and Carr, S. A. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels Mol. Cell. Proteomics 13, 1690-1704
115. Andersen, J. N., Sathyanarayanan, S., Di Bacco, A., Chi, A., Zhang, T., Chen, A. H., Dolinski, B., Kraus, M., Roberts, B., Arthur, W., Klinghoffer, R. A., Gargano, D., Li, L., Feldman, I., Lynch, B., Rush, J., Hendrickson, R. C., Blume-Jensen, P., and Paweletz, C. P. (2011) Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors Sci. Transl. Med. 2, 43ra55
116. Gallien, S. and Domon, B. (2014) Quantitative proteomics using the high resolution accurate mass capabilities of the quadrupole-orbitrap mass spectrometer Bioanalysis 6, 2159-2170
117. Merrill, A. E., Hebert, A. S., MacGilvray, M. E., Rose, C. M., Bailey, D. J., Bradley, J. C., Wood, W. W., El Masri, M., Westphall, M. S., Gasch, A. P., and Coon, J. J. (2014) NeuCode labels for relative protein quantification Mol. Cell. Proteomics 13, 2503-2512
118. Gridling, M., Ficarro, S. B., Breitwieser, F. P., Song, L., Parapatics, K., Colinge, J., Haura, E. B., Marto, J. A., Superti-Furga, G., Bennett, K. L., and Rix, U. (2014) Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics Mol. Cancer. Ther. 13, 2751-2762
119. Demirkan, G., Yu, K., Boylan, J. M., Salomon, A. R., and Gruppuso, P. A. (2011) Phosphoproteomic profiling of in vivo signaling in liver by the mammalian target of rapamycin complex 1 (mTORC1) PLoS One 6, e21729